Resources

Press Release

January 12th, 2026

CytoReason unveils LINA, an AI Agent accelerated by NVIDIA for Pharma R&D, built on computational disease models

Press Release

January 9th, 2026

CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery

Media Coverage

June 6th, 2025

Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond

Media Coverage

April 10th, 2025

Curating Biological Findings from Scientific Literature with NVIDIA NIM

Media Coverage

How top pharma companies boost efficacy

Scientific Publications

June 12th, 2024

Interactions between immune cell types facilitate the evolution of immune traits

Media Coverage

Digital Health 50: The most promising digital health startups of 2024

Press Release

July 17th, 2024

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Blog

May 21st, 2024

Revolutionizing IBD Treatment: The CytoReason and CCF Partnership

Bring your data to life